Viral vaccines and viral vectors used in biotherapeutic applications carry the risk of microbial contamination, which must be addressed.
Priyabrata Pattnaik
Advertisement
Priyabrata Pattnaik, PHD, is head of biologics operations-Asia Pacific, MilliporeSigma.
Articles by Priyabrata Pattnaik
Advertisement
Latest Updated Articles
Ensuring Viral Safety of Viral Vaccines and VectorsSeptember 1st 2018
Advertisement
Advertisement
Trending on BioPharm International
1
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
2
argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal
3
Janux’s JANX011 T-Cell Engager Shows Deep B-Cell Depletion in Phase 1 Healthy Volunteer Study
4
J&J’s Dual-Antigen Bispecific Regimen Achieves 73% PSA Response in Advanced Prostate Cancer
5